» Articles » PMID: 36227357

Combination of Pre-treatment Dynamic [F]FET PET Radiomics and Conventional Clinical Parameters for the Survival Stratification in Patients with IDH-wildtype Glioblastoma

Abstract

Purpose: The aim of this study was to build and evaluate a prediction model which incorporates clinical parameters and radiomic features extracted from static as well as dynamic [F]FET PET for the survival stratification in patients with newly diagnosed IDH-wildtype glioblastoma.

Methods: A total of 141 patients with newly diagnosed IDH-wildtype glioblastoma and dynamic [F]FET PET prior to surgical intervention were included. Patients with a survival time ≤ 12 months were classified as short-term survivors. First order, shape, and texture radiomic features were extracted from pre-treatment static (tumor-to-background ratio; TBR) and dynamic (time-to-peak; TTP) images, respectively, and randomly divided into a training (n = 99) and a testing cohort (n = 42). After feature normalization, recursive feature elimination was applied for feature selection using 5-fold cross-validation on the training cohort, and a machine learning model was constructed to compare radiomic models and combined clinical-radiomic models with selected radiomic features and clinical parameters. The area under the ROC curve (AUC), accuracy, sensitivity, specificity, and positive and negative predictive values were calculated to assess the predictive performance for identifying short-term survivors in both the training and testing cohort.

Results: A combined clinical-radiomic model comprising six clinical parameters and six selected dynamic radiomic features achieved highest predictability of short-term survival with an AUC of 0.74 (95% confidence interval, 0.60-0.88) in the independent testing cohort.

Conclusions: This study successfully built and evaluated prediction models using [F]FET PET-based radiomic features and clinical parameters for the individualized assessment of short-term survival in patients with a newly diagnosed IDH-wildtype glioblastoma. The combination of both clinical parameters and dynamic [F]FET PET-based radiomic features reached highest accuracy in identifying patients at risk. Although the achieved accuracy level remained moderate, our data shows that the integration of dynamic [F]FET PET radiomic data into clinical prediction models may improve patient stratification beyond established prognostic markers.

Citing Articles

Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.

Poursaeed R, Mohammadzadeh M, Safaei A BMC Cancer. 2024; 24(1):1581.

PMID: 39731064 PMC: 11674357. DOI: 10.1186/s12885-024-13320-4.


Radiomics-Based Machine Learning with Natural Gradient Boosting for Continuous Survival Prediction in Glioblastoma.

Karabacak M, Patil S, Gersey Z, Komotar R, Margetis K Cancers (Basel). 2024; 16(21).

PMID: 39518054 PMC: 11544787. DOI: 10.3390/cancers16213614.


-New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates.

Singh G, Singh A, Bae J, Manjila S, Spektor V, Prasanna P Cancer Imaging. 2024; 24(1):133.

PMID: 39375809 PMC: 11460168. DOI: 10.1186/s40644-024-00769-6.


Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis.

Li L, Xiao F, Wang S, Kuang S, Li Z, Zhong Y Sci Rep. 2024; 14(1):16031.

PMID: 38992201 PMC: 11239670. DOI: 10.1038/s41598-024-66653-2.


Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients.

Chantadisai M, Wongwijitsook J, Ritlumlert N, Rakvongthai Y Sci Rep. 2024; 14(1):5001.

PMID: 38424177 PMC: 10904821. DOI: 10.1038/s41598-024-55755-6.


References
1.
Suchorska B, Jansen N, Linn J, Kretzschmar H, Janssen H, Eigenbrod S . Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7):710-9. DOI: 10.1212/WNL.0000000000001262. View

2.
Burgenske D, Yang J, Decker P, Kollmeyer T, Kosel M, Mladek A . Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol. 2019; 21(11):1458-1469. PMC: 6827834. DOI: 10.1093/neuonc/noz129. View

3.
Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M . TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2014; 17(1):45-52. PMC: 4483052. DOI: 10.1093/neuonc/nou158. View

4.
Carles M, Popp I, Starke M, Mix M, Urbach H, Schimek-Jasch T . FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. Radiat Oncol. 2021; 16(1):46. PMC: 7931514. DOI: 10.1186/s13014-020-01744-8. View

5.
Zwanenburg A, Vallieres M, Abdalah M, Aerts H, Andrearczyk V, Apte A . The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020; 295(2):328-338. PMC: 7193906. DOI: 10.1148/radiol.2020191145. View